Gossamer Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Gossamer Bio wird ein Gewinn- und Umsatzwachstum von 29.9% bzw. 36.7% pro Jahr prognostiziert, während der Gewinn pro Aktie um 40.2% pro Jahr wachsen soll.

Wichtige Informationen

29.9%

Wachstumsrate der Gewinne

40.2%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.6%
Wachstumsrate der Einnahmen	36.7%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	09 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:GOSS - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	55	-119	-14	-104	7
12/31/2025	4	-188	-99	-131	7
12/31/2024	114	-72	12	12	7
3/31/2024	N/A	-173	-158	-158	N/A
12/31/2023	N/A	-180	-159	-159	N/A
9/30/2023	N/A	-187	-174	-173	N/A
6/30/2023	N/A	-207	-176	-176	N/A
3/31/2023	N/A	-221	-187	-187	N/A
12/31/2022	N/A	-229	-188	-187	N/A
9/30/2022	N/A	-230	-180	-180	N/A
6/30/2022	N/A	-231	-186	-185	N/A
3/31/2022	N/A	-234	-184	-183	N/A
12/31/2021	N/A	-234	-191	-189	N/A
9/30/2021	N/A	-242	-192	-185	N/A
6/30/2021	N/A	-240	-195	-188	N/A
3/31/2021	N/A	-247	-205	-183	N/A
12/31/2020	N/A	-243	-201	-176	N/A
9/30/2020	N/A	-233	-205	-184	N/A
6/30/2020	N/A	-224	-197	-175	N/A
3/31/2020	N/A	-202	-178	-169	N/A
12/31/2019	N/A	-180	-151	-145	N/A
9/30/2019	N/A	-164	-130	-126	N/A
6/30/2019	N/A	-165	-119	-105	N/A
3/31/2019	N/A	-154	-108	-75	N/A
12/31/2018	N/A	-147	-72	-51	N/A
9/30/2018	N/A	-115	-53	-32	N/A
6/30/2018	N/A	-66	-27	-16	N/A
3/31/2018	N/A	-33	1	-9	N/A
12/31/2017	N/A	-7	N/A	-6	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GOSS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: GOSS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: GOSS wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: GOSSDie Einnahmen des Unternehmens (36.7% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.4% pro Jahr).

Hohe Wachstumseinnahmen: GOSSDie Einnahmen des Unternehmens (36.7% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von GOSS in 3 Jahren voraussichtlich hoch sein wird

Gossamer Bio Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target increased by 15% to US$6.09

Price target decreased by 13% to US$5.18

Price target decreased by 7.9% to US$5.85

Price target decreased by 7.2% to US$7.05

Price target increased by 14% to US$8.20

Price target decreased to US$13.00

Recent updates

Gossamer Bio, Inc. Receives A Written Notice from the Staff Regarding Minimum Bid Price Requirement

Gossamer Bio, Inc., Annual General Meeting, Jun 06, 2024

Gossamer Bio Announces Board of Directors Appointments

Price target increased by 15% to US$6.09

Gossamer Bio Inc. Appoints Bob Smith as Chief Commercial Officer

Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors

Gossamer Bio, Inc. Appoints John Quisel to Its Board of Directors

COO & CFO recently bought US$113k worth of stock

Gossamer Bio Receives Non-Compliance Notice from Nasdaq

Gossamer Bio Receives Non-Compliance Notice from Nasdaq

Gossamer Bio, Inc. Announces Resignation of Kristina Burow from the Board of Directors

Price target decreased by 13% to US$5.18

Price target decreased by 7.9% to US$5.85

Gossamer Bio, Inc. announced that it has received $211.849524 million in funding from a group of investors

New major risk - Shareholder dilution

New major risk - Share price stability

Price target decreased by 7.2% to US$7.05

Price target increased by 14% to US$8.20

Gossamer Bio, Inc., Annual General Meeting, Jun 08, 2023

COO & CFO recently bought US$56k worth of stock

Co-Founder recently bought US$1.0m worth of stock

Price target decreased to US$13.00

Gossamer Bio, Inc. Announces Seralutinib Meets Primary Endpoint in Phase 2 Torrey Study in PAH

Insufficient new directors

Chief Scientific Officer recently sold US$59k worth of stock

Peaking Back In On Gossamer Bio

Price target increased to US$18.64

Price target increased to US$18.10

Price target increased to US$17.60

Gossamer Bio, Inc. announced that it has received $120.041922 million in funding from a group of investors

Gossamer Bio, Inc. announced that it expects to receive $120.041922 million in funding from a group of investors

Gossamer Bio to raise $120M in a private equity placement

Chief Scientific Officer recently sold US$73k worth of stock

Health Check: How Prudently Does Gossamer Bio (NASDAQ:GOSS) Use Debt?

Price target decreased to US$15.80

Insufficient new directors

Gossamer Bio, Inc. Announces Topline Results from its Phase 2 SHIFT-UC Study Clinical Trial Studying GB004 in Patients

Co-Founder recently sold US$170k worth of stock

Insider recently sold US$52k worth of stock

Insider recently sold US$52k worth of stock

Insider recently sold US$52k worth of stock

Gossamer Bio, Inc. to Report Q4, 2021 Results on Mar 03, 2022

Gossamer Bio (NASDAQ:GOSS) Has Debt But No Earnings; Should You Worry?

Price target increased to US$21.25

Insufficient new directors

Price target increased to US$19.50

Is Gossamer Bio (NASDAQ:GOSS) A Risky Investment?

Price target decreased to US$19.00

Gossamer Bio, Inc.(NasdaqGS:GOSS) dropped from Russell 2500 Growth Index

Chief Scientific Officer has left the company

Chief Scientific Officer recently sold US$52k worth of stock

Chief Scientific Officer recently sold US$52k worth of stock

Gossamer Bio, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Need To Know: Gossamer Bio, Inc. (NASDAQ:GOSS) Insiders Have Been Buying Shares

Gossamer Bio, Inc. Announces Executive Changes

Gossamer Bio (GOSS) Investor Presentation - Slideshow

Gossamer Bio Announces Appointment of Faheem Hasnain as Chief Executive Officer

Gossamer Bio, Inc. Provides Clinical-Stage Product Candidate Updates

Gossamer Bio, Inc. to Report Q3, 2020 Results on Nov 10, 2020

New 90-day low: US$8.93

Co-Founder & Chairman recently bought US$1m worth of stock

Gossamer Bio, Inc. Announces Topline Results for Phase 2 Trials of Oral GB001 in Asthma and Chronic Rhinosinusitis

Price target lowered to US$26.13

New 90-day low: US$10.09

Gossamer Bio Announces Presentation of GB004 Phase 1b Clinical Data at United European Gastroenterology Virtual Week 2020 and Additional Program Updates

New 90-day low: US$11.30

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie